Advertisement

Lobular Neoplasia

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lakhani S.R.
        • International Agency for Research on Cancer
        2nd edition. WHO classification of breast tumours: WHO classification of tumours. vol. 2. IARC, Lyon, France2019 (Who Classification of Tumours Editorial Board)
        • London S.J.
        • Connolly J.L.
        • Schnitt S.J.
        • et al.
        A prospective study of benign breast disease and the risk of breast cancer.
        JAMA. 1992; 267: 941-944
        • Page D.L.
        • Dupont W.D.
        • Rogers L.W.
        • et al.
        Atypical hyperplastic lesions of the female breast: a long-term follow-up study.
        Cancer. 1985; 55: 2698-2708
        • Simpson P.T.
        • Gale T.
        • Fulford L.G.
        • et al.
        The diagnosis and management of pre-invasive breast disease: pathology of atypical lobular hyperplasia and lobular carcinoma in situ.
        Breast Cancer Res. 2003; 5: 258-262
        • Ewing J.
        Neoplastic diseases: a textbook on tumors.
        WB Saunders, Philadelphia1919
        • Foote Jr., F.W.
        • Stewart F.W.
        Lobular carcinoma in situ. A rare form of mammary cancer.
        Am J Pathol. 1941; 17: 491-496
        • Haagensen C.D.
        • Lane N.
        • Lattes R.
        • et al.
        Lobular neoplasia (so-called lobular carcinoma in situ) of the breast.
        Cancer. 1978; 42: 737-769
        • Lee J.Y.
        • Schizas M.
        • Geyer F.C.
        • et al.
        Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.
        Clin Cancer Res. 2019; 25: 674-686
        • Andrade V.P.
        • Ostrovnaya I.
        • Seshan V.E.
        • et al.
        Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions.
        Breast Cancer Res. 2012; 14: R103
        • Begg C.B.
        • Ostrovnaya I.
        • Carniello J.V.
        • et al.
        Clonal relationships between lobular carcinoma in situ and other breast malignancies.
        Breast Cancer Res. 2016; 18: 66
      1. National Comprehensive Cancer Network. Breast Cancer Screening and Diagnosis.
        (Available at:) (Accessed April 1, 2022)
        • Page D.L.
        • Rogers L.W.
        Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia.
        Hum Pathol. 1992; 23: 1095-1097
        • Jain R.K.
        • Mehta R.
        • Dimitrov R.
        • et al.
        Atypical ductal hyperplasia: interobserver and intraobserver variability.
        Mod Pathol. 2011; 24: 917-923
        • Chen Y.Y.D.T.
        • King T.A.
        • Palacios J.
        • et al.
        Lobular carcinoma in situ.
        in: Board T.W.C.E. Breast Tumours. International Agency for Research on Cancer, Lyon (France)2019: 71-74
        • Chen Y.Y.
        • Hwang E.S.
        • Roy R.
        • et al.
        Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.
        Am J Surg Pathol. 2009; 33: 1683-1694
        • Dabbs D.J.
        • Schnitt S.J.
        • Geyer F.C.
        • et al.
        Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.
        Am J Surg Pathol. 2013; 37: 1-11
        • Beute B.J.
        • Kalisher L.
        • Hutter R.V.
        Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features.
        AJR Am J Roentgenol. 1991; 157: 257-265
        • Maxwell A.J.
        • Clements K.
        • Dodwell D.J.
        • et al.
        The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project.
        Breast. 2016; 27: 109-115
        • Eusebi V.
        • Magalhaes F.
        • Azzopardi J.G.
        Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation.
        Hum Pathol. 1992; 23: 655-662
        • Sneige N.
        • Wang J.
        • Baker B.A.
        • et al.
        Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
        Mod Pathol. 2002; 15: 1044-1050
        • Alvarado-Cabrero I.
        • Picon Coronel G.
        • Valencia Cedillo R.
        • et al.
        Florid lobular intraepithelial neoplasia with signet ring cells, central necrosis and calcifications: a clinicopathological and immunohistochemical analysis of ten cases associated with invasive lobular carcinoma.
        Arch Med Res. 2010; 41: 436-441
        • Shamir E.R.
        • Chen Y.Y.
        • Chu T.
        • et al.
        Pleomorphic and florid lobular carcinoma in situ variants of the breast: a clinicopathologic study of 85 cases with and without invasive carcinoma from a single academic center.
        Am J Surg Pathol. 2019; 43: 399-408
        • Lopez-Garcia M.A.
        • Geyer F.C.
        • Lacroix-Triki M.
        • et al.
        Breast cancer precursors revisited: molecular features and progression pathways.
        Histopathology. 2010; 57: 171-192
        • Mastracci T.
        • Tjan S.
        • Bane A.
        • et al.
        E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast.
        Mod Pathol. 2005; 18: 741-751
        • Sarrio D.
        • Moreno-Bueno G.
        • Hardisson D.
        • et al.
        Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
        Int J Cancer. 2003; 106: 208-215
        • Derksen P.W.
        • Liu X.
        • Saridin F.
        • et al.
        Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.
        Cancer Cell. 2006; 10: 437-449
        • Weigelt B.
        • Geyer F.C.
        • Natrajan R.
        • et al.
        The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.
        J Pathol. 2010; 220: 45-57
        • Lu Y.J.
        • Osin P.
        • Lakhani S.R.
        • et al.
        Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia.
        Cancer Res. 1998; 58: 4721-4727
        • Ciriello G.
        • Gatza M.L.
        • Beck A.H.
        • et al.
        Comprehensive molecular portraits of invasive lobular breast cancer.
        Cell. 2015; 163: 506-519
        • Swanton C.
        • McGranahan N.
        • Starrett G.J.
        • et al.
        APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity.
        Cancer Discov. 2015; 5: 704-712
        • Li C.I.
        • Malone K.E.
        • Saltzman B.S.
        • et al.
        Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001.
        Cancer. 2006; 106: 2104-2112
        • Reis-Filho J.S.
        • Pusztai L.
        Gene expression profiling in breast cancer: classification, prognostication, and prediction.
        Lancet. 2011; 378: 1812-1823
        • Dupont W.D.
        • Page D.L.
        Risk factors for breast cancer in women with proliferative breast disease.
        N Engl J Med. 1985; 312: 146-151
        • Hartmann L.C.
        • Schaid D.J.
        • Woods J.E.
        • et al.
        Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
        N Engl J Med. 1999; 340: 77-84
        • Page D.L.
        • Kidd Jr., T.E.
        • Dupont W.D.
        • et al.
        Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease.
        Hum Pathol. 1991; 22: 1232-1239
        • King T.A.
        • Pilewskie M.
        • Muhsen S.
        • et al.
        Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.
        J Clin Oncol. 2015; 33: 3945-3952
        • Bodian C.A.
        • Perzin K.H.
        • Lattes R.
        Lobular neoplasia. Long term risk of breast cancer and relation to other factors.
        Cancer. 1996; 78: 1024-1034
        • Chuba P.J.
        • Hamre M.R.
        • Yap J.
        • et al.
        Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: Analysis of Surveillance, Epidemiology, and End Results data.
        J Clin Oncol. 2005; 23: 5534-5541
        • Collins L.C.
        • Aroner S.A.
        • Connolly J.L.
        • et al.
        Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.
        Cancer. 2016; 122: 515-520
        • Degnim A.C.
        • Dupont W.D.
        • Radisky D.C.
        • et al.
        Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.
        Cancer. 2016; 122: 2971-2978
        • Valero M.G.
        • Zabor E.C.
        • Park A.
        • et al.
        The Tyrer-Cuzick Model Inaccurately Predicts Invasive Breast Cancer Risk in Women With LCIS.
        Ann Surg Oncol. 2020; 27: 736-740
        • Pankratz V.S.
        • Hartmann L.C.
        • Degnim A.C.
        • et al.
        Assessment of the accuracy of the Gail model in women with atypical hyperplasia.
        J Clin Oncol. 2008; 26: 5374-5379
        • Frykberg E.R.
        Lobular carcinoma in situ of the breast.
        Breast J. 1999; 5: 296-303
        • Hussain M.
        • Cunnick G.H.
        Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast: A review.
        Eur J Surg Oncol. 2011; 37: 279-289
        • Portschy P.R.
        • Marmor S.
        • Nzara R.
        • et al.
        Trends in incidence and management of lobular carcinoma in situ: A population-based analysis.
        Ann Surg Oncol. 2013; 20: 3240-3246
      2. The American Society of Breast Surgeons. Position Statement on Screening Mammography.
        (Available at:) (Assessed April 1, 2022)
        • Hwang H.
        • Barke L.D.
        • Mendelson E.B.
        • et al.
        Atypical lobular hyperplasia and classic lobular carcinoma in situ in core biopsy specimens: routine excision is not necessary.
        Mod Pathol. 2008; 21: 1208-1216
        • Menon S.
        • Porter G.J.
        • Evans A.J.
        • et al.
        The significance of lobular neoplasia on needle core biopsy of the breast.
        Virch Arch. 2008; 452: 473-479
        • Purdie C.A.
        • McLean D.
        • Stormonth E.
        • et al.
        Management of in situ lobular neoplasia detected on needle core biopsy of breast.
        J Clin Pathol. 2010; 63: 987-993
        • Niell B.
        • Specht M.
        • Gerade B.
        • et al.
        Is excisional biopsy required after a breast core biopsy yields lobular neoplasia?.
        AJR Am J Roentgenol. 2012; 199: 929-935
        • Rendi M.H.
        • Dintzis S.M.
        • Lehman C.D.
        • et al.
        Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy.
        Ann Surg Oncol. 2012; 19: 914-921
        • Shah-Khan M.G.
        • Geiger X.J.
        • Reynolds C.
        • et al.
        Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy.
        Ann Surg Oncol. 2012; 19: 3131-3138
        • Atkins K.A.
        • Cohen M.A.
        • Nicholson B.
        • et al.
        Atypical lobular hyperplasia and lobular carcinoma in situ at core breast biopsy: use of careful radiologic-pathologic correlation to recommend excision or observation.
        Radiology. 2013; 269: 340-347
        • Chaudhary S.
        • Lawrence L.
        • McGinty G.
        • et al.
        Classic lobular neoplasia on core biopsy: a clinical and radio-pathologic correlation study with follow-up excision biopsy.
        Mod Pathol. 2013; 26: 762-771
        • Murray M.P.
        • Luedtke C.
        • Liberman L.
        • et al.
        Classic lobular carcinoma in situ and atypical lobular hy- perplasia at percutaneous breast core biopsy: outcomes of prospective excision.
        Cancer. 2013; 119: 1073-1079
        • Mooney K.L.
        • Bassett L.W.
        • Apple S.K.
        Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.
        Mod Pathol. 2016; 29: 1471-1484
        • Nakhlis F.
        • Gilmore L.
        • Gelman R.
        • et al.
        Incidence of adjacent synchronous invasive carcinoma and/or ductal carcinoma in-situ in patients with lobular neoplasia on core biopsy: results from a prospective multi-institutional registry (TBCRC 020).
        Ann Surg Oncol. 2016; 23: 722-728
        • Sen L.Q.
        • Berg W.A.
        • Hooley R.J.
        • et al.
        Core breast biopsies showing lobular carcinoma in situ should be excised and surveillance is reasonable for atypical lobular hyperplasia.
        AJR Am J Roentgenol. 2016; 207: 1132-1145
        • Susnik B.
        • Day D.
        • Abeln E.
        • et al.
        Surgical outcomes of lobular neoplasia diagnosed in core biopsy: prospective study of 316 cases.
        Clin Breast Cancer. 2016; 16: 507-513
        • Muller K.E.
        • Roberts E.
        • Zhao L.
        • et al.
        Isolated atypical lobular hyperplasia diagnosed on breast biopsy: low upgrade rate on subse- quent excision with long-term follow-up.
        Arch Pathol Lab Med. 2018; 142: 391-395
        • Schmidt H.
        • Arditi B.
        • Wooster M.
        • et al.
        Observation versus excision of lobular neoplasia on core needle biopsy of the breast.
        Breast Cancer Res Treat. 2018; 168: 649-654
        • Holbrook A.I.
        • Hanley K.
        • Jeffers C.
        • et al.
        Triaging Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ on Percutaneous Core Biopsy to Surgery or Observation: Assiduous Radiologic-Pathologic Correlation Works, Quantitating Extent of Disease Does Not.
        Arch Pathol Lab Med. 2019; 143: 621-627
        • Li X.
        • Ma Z.
        • Styblo T.M.
        • Arciero C.A.
        • Wang H.
        • Cohen M.A.
        Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high risk breast lesion conferences at an academic institution. Breast cancer research and.
        treatment. 2021; 185: 573-581
        • Pride R.M.
        • Jimenez R.E.
        • Hoskin T.L.
        • et al.
        Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ.
        Surgery. 2021; 169: 644-648
        • Laws A.
        • Katlin F.
        • Nakhlis F.
        • et al.
        Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision.
        Ann Surg Oncol. 2022; 29: 1660-1667
        • Nakhlis F.
        • Harrison B.T.
        • Giess C.S.
        • et al.
        Evaluating the rate of upgrade to invasive breast cancer and/or ductal carcinoma in situ following a core biopsy diagnosis of non-classic lobular carcinoma in situ.
        Ann Surg Oncol. 2019; 26: 55-61
        • Kuba M.G.
        • Murray M.P.
        • Coffey K.
        • et al.
        Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.
        Mod Pathol. 2021; 34: 1495-1506
        • Flanagan M.R.
        • Rendi M.H.
        • Calhoun K.E.
        • et al.
        Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management.
        Ann Surg Oncol. 2015; 22: 4263-4269
        • Downs-Kelly E.
        • Bell D.
        • Perkins G.H.
        • et al.
        Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ.
        Arch Pathol Lab Med. 2011; 135: 737-743
        • Sullivan M.E.
        • Khan S.A.
        • Sullu Y.
        • et al.
        Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications.
        Arch Pathol Lab Med. 2010; 134: 1024-1028
        • Chivukula M.
        • Haynik D.M.
        • Brufsky A.
        • et al.
        Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
        Am J Surg Pathol. 2008; 32: 1721-1726
        • Blair S.L.
        • Emerson D.K.
        • Kulkarni S.
        • et al.
        Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ.
        Breast J. 2013; 19: 116-118
        • Moran M.
        • Haffty B.G.
        Lobular carcinoma in situ as a component of breast cancer: the long-term outcome in patients treated with breast conservation therapy.
        Int J Radiat Oncol Biol Phys. 1998; 40: 353-358
        • Khoury T.
        • Karabakhtsian R.G.
        • Mattson D.
        • et al.
        Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases.
        Histopathology. 2014; 64: 981-993
        • Monticciolo D.L.
        • Newell M.S.
        • Moy L.
        • et al.
        Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR.
        J Am Coll Radiol. 2018; 15: 408-414
      3. American Cancer Society. Lobular Carcinoma in Situ.
        (Available at:) (Accessed April 1, 2022)
        • Nadler M.
        • Al-Attar H.
        • Warner E.
        • et al.
        MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.
        Breast. 2017; 34: 77-82
        • King T.A.
        • Muhsen S.
        • Patil S.
        • et al.
        Is there a role for routine screening MRI in women with LCIS?.
        Breast Cancer Res Treat. 2013; 142: 445-453
        • Tilanus-Linthorst M.M.
        • Obdeijn I.M.
        • Hop W.C.
        • et al.
        BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
        Clin Cancer Res. 2007; 13: 7357-7362
        • Fisher B.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
        J Natl Cancer Inst. 1998; 90: 1371-1388
        • Vogel V.G.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
        JAMA. 2006; 295: 2727-2741
        • Goss P.E.
        • Ingle J.N.
        • Ales-Martinez J.E.
        • et al.
        Exemestane for breast-cancer prevention in postmenopausal women.
        N Engl J Med. 2011; 364: 2381-2391
        • Cuzick J.
        • Sestak I.
        • Forbes J.F.
        • et al.
        IBIS-II investigators. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
        Lancet. 2020; 395: 117-122
        • Noonan S.
        • Pasa A.
        • Fontana V.
        • et al.
        A survey among breast cancer specialists on the low uptake of therapeutic prevention with tamoxifen or raloxifene.
        Cancer Prev Res (Phila). 2018; 11: 38-43
        • Land S.R.
        • Walcott F.L.
        • Liu Q.
        • et al.
        Symptoms and QOL as predictors of chemoprevention adherence in NRG Oncology/NSABP Trial P-1.
        J Natl Cancer Inst. 2015; 108: djv365
        • Ropka M.E.
        • Keim J.
        • Philbrick J.T.
        Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.
        J Clin Oncol. 2010; 28: 3090-3095
        • Port E.R.
        • Montgomery L.L.
        • Heerdt A.S.
        • et al.
        Patient reluctance toward tamoxifen use for breast cancer primary prevention.
        Ann Surg Oncol. 2001; 8: 580-585
        • Bambhroliya A.
        • Chavez-MacGregor M.
        • Brewster A.M.
        Barriers to the use of breast cancer risk reduction therapies.
        J Natl Compr Canc Netw. 2015; 13: 927-935
        • Brewster A.M.
        • Thomas P.
        • Brown P.
        • et al.
        A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ.
        Cancer Prev Res. 2018; 11: 295-302
        • DeCensi A.
        • Puntoni M.
        • Guerrieri-Gonzaga A.
        • et al.
        Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
        J Clin Oncol. 2019; 37: 1629-1637
        • Taylor L.J.
        • Steiman J.
        • Schumacher J.R.
        • et al.
        Surgical Management of Lobular Carcinoma In Situ: Analysis of the National Cancer Database.
        Ann Surg Oncol. 2018; 25: 2229-2234
        • Geiger A.M.
        • Yu O.
        • Herrinton L.J.
        • et al.
        A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices.
        Arch Intern Med. 2005; 165: 516-520
        • Sakurai T.
        • Zhang N.
        • Suzuma T.
        • et al.
        Long-term follow-up of nipple-sparing mastectomy without radiotherapy: a single center study at a Japanese institution.
        Med Oncol. 2013; 30: 481
        • Jakub J.W.
        • Peled A.W.
        • Gray R.J.
        • et al.
        Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
        JAMA Surg. 2018; 153: 123-129
        • Balch C.
        • Klimberg V.S.
        • Pawlik T.
        • et al.
        Textbook of complex general surgical oncology.
        McGraw-Hill, New York, USA2016